MARY DANKS

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. ncbi request reprint Structural insights into CPT-11 activation by mammalian carboxylesterases
    Sompop Bencharit
    Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Nat Struct Biol 9:337-42. 2002
  2. ncbi request reprint A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38
    Hilde Stubdal
    Onyx Pharmaceuticals, Richmond, California 94806, USA
    Cancer Res 63:6900-8. 2003
  3. ncbi request reprint Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma
    Mary K Danks
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Cancer Res 67:22-5. 2007
  4. ncbi request reprint Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report
    Alberto Broniscer
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Clin Cancer Res 13:6712-8. 2007
  5. ncbi request reprint Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan
    Edyta Tyminski
    Molecular Neuro oncology Laboratories, Neurosurgery Service and Biostatistics Center, Massachusetts General Hospital, Charlestown, Massachusetts, USA
    Cancer Res 65:6850-7. 2005
  6. ncbi request reprint Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy
    K Jin Yoon
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Mol Cancer Ther 5:1577-84. 2006
  7. ncbi request reprint Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity
    Janice L Hyatt
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105 2794, USA
    Mol Cancer Ther 5:2281-8. 2006
  8. ncbi request reprint Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study
    Maryam Fouladi
    St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 107:2291-7. 2006
  9. ncbi request reprint Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-beta and restricts tumor growth in a murine model of disseminated neuroblastoma
    Paxton V Dickson
    Department of Surgery, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Pediatr Surg 42:48-53. 2007
  10. ncbi request reprint Selective inhibition of carboxylesterases by isatins, indole-2,3-diones
    Janice L Hyatt
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, and Department of Chemistry and Biochemistry, University of Mississippi, University, Mississippi 38677, USA
    J Med Chem 50:1876-85. 2007

Research Grants

  1. SELECTIVE THERAPY OF NEUROBLASTOMA
    MARY DANKS; Fiscal Year: 2007
  2. Neural Progenitor Cells as Cancer Therapy Vectors
    MARY DANKS; Fiscal Year: 2007

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Structural insights into CPT-11 activation by mammalian carboxylesterases
    Sompop Bencharit
    Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Nat Struct Biol 9:337-42. 2002
    ..These results may facilitate the design of improved anticancer drugs or enzymes for use in viral-directed cancer cotherapies...
  2. ncbi request reprint A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38
    Hilde Stubdal
    Onyx Pharmaceuticals, Richmond, California 94806, USA
    Cancer Res 63:6900-8. 2003
    ..These results indicate that the addition of a prodrug converting enzyme may be a feasible approach to additionally enhance the efficacy of replicating adenoviruses as cancer therapeutics...
  3. ncbi request reprint Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma
    Mary K Danks
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Cancer Res 67:22-5. 2007
    ..NDEPT approaches merit further investigation as effective, targeted therapy for metastatic tumors. We propose that the described approach may have greatest use for eradicating minimum residual disease...
  4. ncbi request reprint Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report
    Alberto Broniscer
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Clin Cancer Res 13:6712-8. 2007
    ..To estimate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of escalating doses of temozolomide combined with O(6)-benzylguanine in patients < or =21 years with recurrent brain tumors...
  5. ncbi request reprint Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan
    Edyta Tyminski
    Molecular Neuro oncology Laboratories, Neurosurgery Service and Biostatistics Center, Massachusetts General Hospital, Charlestown, Massachusetts, USA
    Cancer Res 65:6850-7. 2005
    ..Therefore, MGH2 provides effective multimodal therapy for gliomas in preclinical models when combined with these chemotherapy agents...
  6. ncbi request reprint Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy
    K Jin Yoon
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Mol Cancer Ther 5:1577-84. 2006
    ..These data provide proof-of-principle that enzyme-prodrug therapy approaches comprised of prodrugs with complementary mechanisms of cytotoxicity that are activated by a single enzyme can be developed...
  7. ncbi request reprint Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity
    Janice L Hyatt
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105 2794, USA
    Mol Cancer Ther 5:2281-8. 2006
    ..These results suggest that intracellular modulation of carboxylesterase activity with benzil or its analogues may be applied to minimize the toxicity of normal cells to CPT-11...
  8. ncbi request reprint Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study
    Maryam Fouladi
    St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 107:2291-7. 2006
    ....
  9. ncbi request reprint Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-beta and restricts tumor growth in a murine model of disseminated neuroblastoma
    Paxton V Dickson
    Department of Surgery, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Pediatr Surg 42:48-53. 2007
    ..We investigated the potential of targeted delivery using tumor-tropic neural progenitor cells (NPCs) transduced to express human IFN-beta (hIFN-beta)...
  10. ncbi request reprint Selective inhibition of carboxylesterases by isatins, indole-2,3-diones
    Janice L Hyatt
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, and Department of Chemistry and Biochemistry, University of Mississippi, University, Mississippi 38677, USA
    J Med Chem 50:1876-85. 2007
    ..While the isatin analogues were generally less effective at CE inhibition than the benzils, the former may represent valid lead compounds for the development of inhibitors for use in modulating drug metabolism in vivo...
  11. ncbi request reprint Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma
    Lars M Wagner
    Division of Pediatric Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Clin Cancer Res 13:5418-25. 2007
    ..We hypothesized that the DNA repair protein methylguanine-DNA methyltransferase (MGMT) is an important resistance factor, and that inactivation of MGMT would sensitize neuroblastoma cells to these agents...
  12. ncbi request reprint Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1
    Janice L Hyatt
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    J Med Chem 50:5727-34. 2007
    ..001) between the dione dihedral angle and the preferential inhibition of either hiCE or hCE1. Overall, the results presented here define the parameters necessary for small molecule inhibition of human CEs...
  13. ncbi request reprint Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases
    Randy M Wadkins
    Department of Chemistry and Biochemistry, University of Mississippi, University, Mississippi 38677, USA
    J Med Chem 48:2906-15. 2005
    ..91), with cross-validation coefficients (q(2)) of 0.9. Overall, these results suggest that selective inhibitors of CEs with potential for use in clinical applications can be designed...
  14. ncbi request reprint Development of prodrugs for enzyme-mediated, tumor-selective therapy
    K Jin Yoon
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Curr Med Chem Anticancer Agents 5:107-13. 2005
    ..This mini-review evaluates and compares characteristics of seven selected enzyme/prodrug combinations, and discusses goals for future development of effective combinations...
  15. ncbi request reprint Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients
    Lars M Wagner
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer Res 62:5001-7. 2002
    ..Assessment of purging efficacy with additional samples from NB patients is ongoing...
  16. ncbi request reprint p53-mediated regulation of expression of a rabbit liver carboxylesterase confers sensitivity to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11)
    Monika Wierdl
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    J Pharmacol Exp Ther 304:699-705. 2003
    ..These studies indicate that the inactivation of wtp53 by mutant p53 in human tumor cells may be sufficient enough to generate a therapeutic window for enhanced cytotoxicity with CPT-11...
  17. ncbi request reprint Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition
    Sompop Bencharit
    Department of Chemistry, School of Dentistry, University of North Carolina, Chapel Hill, 27599, USA
    Chem Biol 10:341-9. 2003
    ..Further, we use our structure to identify tacrine derivatives that act as low-micromolar inhibitors of hCE1 and may provide new avenues for treating narcotic abuse and cholesterol-related diseases...
  18. ncbi request reprint Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance
    Monika Wierdl
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Mol Pharmacol 64:279-88. 2003
    ..These studies indicate that overexpression of ABCG2 in vivo would probably overcome any increased drug activation that might be achieved by gene delivery or antibody-directed enzyme prodrug therapy methods using rCE...
  19. ncbi request reprint Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies
    Kyoung Jin P Yoon
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, TN 38015, USA
    Mol Cancer Ther 2:1171-81. 2003
    ..This was confirmed by both growth inhibition experiments and kinetic studies. The method is being used to design camptothecin prodrugs predicted to be activated by specific CEs...
  20. ncbi request reprint Enzyme-prodrug systems: carboxylesterase/CPT-11
    Mary K Danks
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, TN, USA
    Methods Mol Med 90:247-62. 2004
  21. ncbi request reprint Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity
    Randy M Wadkins
    Department of Chemistry and Biochemistry, University of Mississippi, University, USA
    Mol Pharmacol 65:1336-43. 2004
    ..These and other phenyl-substituted sulfonamides compounds are regarded as lead compounds for the development of effective, selective CE inhibitors for clinical applications...
  22. ncbi request reprint Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application
    Kyoung Jin P Yoon
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 3810, USA
    Mol Cancer Ther 3:903-9. 2004
    ..The four compounds characterized in this study will serve as lead compounds for a series of inhibitors to be constructed using a combinatorial approach...
  23. ncbi request reprint Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR
    Lars M Wagner
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    J Pediatr Hematol Oncol 28:635-41. 2006
    ..The selective expression of MYCN in tumor cells, and the sensitivity of detection of MYCN by RT-PCR noted in this and other studies, supports further evaluation of MYCN as a NB marker for molecular detection of minimal residual disease...
  24. ncbi request reprint Translocations of 17q21 approximately qter in neuroblastoma cell lines infrequently include the topoisomerase IIalpha gene
    K Jin Yoon
    Cancer Genet Cytogenet 167:92-4. 2006
  25. ncbi request reprint P21Waf1/Cip1 dysfunction in neuroblastoma: a novel mechanism of attenuating G0-G1 cell cycle arrest
    Pamela P McKenzie
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer Res 63:3840-4. 2003
    ..Cdk inhibitors currently being developed for clinical use may be useful therapy for tumors such as NB in which endogenous cdk inhibitors are defective...
  26. ncbi request reprint Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety
    Janice L Hyatt
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, Tennessee 38105, USA
    J Med Chem 48:5543-50. 2005
    ..Overall, these studies identify subdomains within the aromatic ethane-1,2-diones, that are responsible for CE inhibition...
  27. ncbi request reprint Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice
    Christopher L Morton
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Cancer Chemother Pharmacol 56:629-36. 2005
    ..To examine the antitumor activity and the pharmacokinetics of CPT-11 (irinotecan, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) in a plasma esterase-deficient scid mouse model, bearing human tumor xenografts...

Research Grants8

  1. SELECTIVE THERAPY OF NEUROBLASTOMA
    MARY DANKS; Fiscal Year: 2007
    ..Overall, these studies should provide alternative treatment modalities for high-risk neuroblastoma. ..
  2. Neural Progenitor Cells as Cancer Therapy Vectors
    MARY DANKS; Fiscal Year: 2007
    ..The described approach might then be adapted to the treatment of other solid tumors by careful choice of appropriate therapeutic transgenes. ..